Anti-Leucine-Rich Glioma Inactivated Gene 1 (LGI1) Antibody
CAT:
14-56577-1
Size:
100 µg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Anti-Leucine-Rich Glioma Inactivated Gene 1 (LGI1) Antibody
- Description: Mouse Monoclonal Antibody specific to Leucine-Rich Glioma Inactivated Gene 1 (LGI1)
- Product Name Alternative: Anti-Leucine-Rich Glioma Inactivated Gene 1 (LGI1) Mouse Monoclonal Antibody
- CAS Number: 9007-83-4
- Gene Name: Lgi1
- NCBI Gene ID: Lgi1
- UniProt: Q9JIA1.1
- Host: Mouse
- Reactivity: Human, Mouse, Rat
- Immunogen: Fusion protein corresponding to aa 37-113 of mouse LGI1. This sequence is 100
- Target Antigen: Leucine-rich glioma-inactivated protein 1
- Target: Leucine-Rich Glioma Inactivated Gene 1 (LGI1)
- Clonality: Monoclonal
- Isotype: IgG2a
- Type: Antibody
- Applications: WB, IHC, ICC/IF
- Field of Research: Neuroscience
- Purification Method: Purified by Protein G affinity chromatography
- Concentration: 1.0 mg/mL
- Dilution: Dilute in PBS or medium that is identical to that used in the assay system.
- Format: Purified
- Form: Liquid
- Buffer: Phosphate Buffered Saline
- Additionnal Information: Immunoblotting: use at 1-5ug/mL. A band of ~60kDa is detected.
Immunofluorescence: use at 10ug/mL.
These are recommended concentrations.
Endusers should determine optimal concentrations for their application. - Storage Conditions: This product is stable for at least one (1) year at -20°C.
- Specificity: This antibody recognizes human, mouse, and rat LGI1.
- Formulation: PBS, pH 7.4, 0.1% sodium azide, 50% glycerol.
- Buffer pH: pH 7.4
- Target Background: The leucine-rich glioma inactivated -1 (LGI1) gene is rearranged as a result of translocations in glioblastoma cell lines. This protein contains a hydrophobic segment representing a putative transmembrane domain with the amino terminus located outside the cell. It also contains leucine- rich repeats with conserved cysteine-rich flanking sequences. This gene is predominantly expressed in neural tissues and its expression is reduced in low grade brain tumors and significantly reduced or absent in malignant gliomas.